Selective serotonin reuptake inhibitor-induced rhabdomyolysis associated with irinotecan

South Med J. 2003 Oct;96(10):1031-3. doi: 10.1097/01.SMJ.0000084311.35864.D6.

Abstract

A 74-year-old man was admitted with rhabdomyolysis after undergoing initial treatment for gastrointestinal cancer with irinotecan. The syndrome partially resolved after the discontinuation of all of his usual medications, including his chronic selective serotonin reuptake inhibitor (SSRI). The rhabdomyolysis was exacerbated upon reinitiation of the SSRI and disappeared when the SSRI was discontinued. The combination of irinotecan and SSRI resulted in potentially lethal rhabdomyolysis.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / drug therapy
  • Aged
  • Antineoplastic Agents, Phytogenic / adverse effects*
  • Camptothecin / adverse effects*
  • Camptothecin / analogs & derivatives*
  • Citalopram / adverse effects*
  • Depressive Disorder / drug therapy
  • Drug Interactions
  • Gastrointestinal Neoplasms / drug therapy
  • Humans
  • Irinotecan
  • Male
  • Rhabdomyolysis / chemically induced*
  • Selective Serotonin Reuptake Inhibitors / adverse effects*

Substances

  • Antineoplastic Agents, Phytogenic
  • Serotonin Uptake Inhibitors
  • Citalopram
  • Irinotecan
  • Camptothecin